Aptinyx Inc represents a corporate philosophy centered around innovation, patient-centricity, and scientific excellence. As a leading biopharmaceutical company, Aptinyx is dedicated to developing novel therapies that address significant unmet medical needs in the field of neuroscience. The company's core values include a commitment to groundbreaking research, cutting-edge technology, and collaboration with academic and industry partners. Aptinyx aims to improve the lives of patients and their families by advancing transformative medicines. Through their steadfast dedication and emphasis on scientific rigor, Aptinyx Inc is at the forefront of discovering innovative solutions for neurological disorders.

Aptinyx Inc is primarily present in the United States.

Some significant milestones achieved by Aptinyx Inc include the successful completion of Phase 2 clinical trials for their lead drug candidate, NYX-2925, in the treatment of chronic pain and post-traumatic stress disorder (PTSD). Additionally, Aptinyx Inc has presented positive data demonstrating the drug's potential benefits in improving cognitive function and reducing symptoms associated with central nervous system disorders. The company has also collaborated with prominent organizations and received grants, reflecting its recognition in the field. With these achievements, Aptinyx Inc is positioned as a promising player in the development of innovative therapies for neurological and psychiatric disorders.

Aptinyx Inc. is a biopharmaceutical company specializing in the discovery and development of novel therapies to treat brain and nervous system disorders. Founded in 2015, Aptinyx is headquartered in Evanston, Illinois. The company focuses on the development of selective N-methyl-D-aspartate (NMDA) receptor modulators, which have the potential to address a range of neurological and psychiatric conditions. Aptinyx's pipeline includes drug candidates targeting conditions such as chronic pain, Parkinson's disease, and post-traumatic stress disorder (PTSD). With a commitment to improving patients' lives, Aptinyx is dedicated to advancing its innovative therapies through rigorous clinical trials and regulatory processes.

The main competitors of Aptinyx Inc in the market include other pharmaceutical companies operating in the field of neuroscience and developing novel therapies for central nervous system disorders. These competitors may include companies such as Biogen Inc., Celgene Corporation, and Johnson & Johnson.

Aptinyx Inc is primarily active in the biotechnology and pharmaceutical industries.

Aptinyx Inc's business model revolves around developing and commercializing novel therapies for treating neurological disorders. The company primarily focuses on targeting the brain's N-methyl-D-aspartate (NMDA) receptor pathway to address conditions such as post-traumatic stress disorder (PTSD), neuropathic pain, and cognitive dysfunction. By utilizing a proprietary platform, Aptinyx aims to bring innovative medicines to market that can provide significant benefits to patients in need. Through strategic collaborations and advancements in neuroscience research, Aptinyx strives to create value for its shareholders while improving patient outcomes in the field of neurology.

Aptinyx P/E suhe on −0,21.

Aptinyx KUV on 0.

AlleAktien kvaliteediskoor ettevõttele Aptinyx on 1/10.

Praegu ei saa Aptinyx käivet arvutada.

oodatud Aptinyx kasum on −30,39 mln. USD.

Aptinyx Inc is a biopharmaceutical company specializing in the development of novel therapeutics for the central nervous system. Founded in 2015 in Evanston, Illinois, Aptinyx focuses on discovering revolutionary therapies with a focus on neuromodulatory agents that can modify the brain's signaling systems. The business model of Aptinyx is based on identifying new target molecules, developing new drugs, and conducting clinical trials to assess the safety and efficacy of the drugs. The company also has partnerships with other pharmaceutical companies that support the discovery and development of new therapeutics. Aptinyx is dedicated to developing effective therapies for neurological disorders such as chronic pain, neuropathic pain, post-traumatic stress disorder (PTSD), and other conditions. The company operates in various areas and has multiple product candidates at different stages of development, from exploration to clinical development. One of these product candidates is NYX-784, a modulatory agent primarily used for the treatment of neuropathies and chronic pain. Aptinyx initiated clinical trials for NYX-784 in 2020. Another product candidate is NYX-458, a medication for the treatment of central sensitization conditions such as fibromyalgia or migraines. Clinical trials for NYX-458 are also being planned. The company also offers services in various areas, including the identification of novel targets and molecules, drug development, and the conduct of clinical trials. Aptinyx's services are aimed at both other pharmaceutical companies and academic institutes. Aptinyx also has partnerships with other companies in the pharmaceutical and biotech industry. In 2019, Aptinyx and Allergan entered into an agreement for the development and commercialization of NYX-2925, a medication for the treatment of depression. The agreement also includes Allergan acquiring a majority stake in Aptinyx valued at approximately $125 million. Overall, Aptinyx's business model has the potential to radically improve the treatment of neurological disorders. With a strong pipeline of product candidates, significant partnerships, and a dedicated team of researchers and developers, the company is on track to make a real difference in the field of neuromodulatory therapies.

Aptinyx maksab dividendi 0 USD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Aptinyx jaoks arvutada või ettevõte ei maksa dividende välja.

Aptinyx ISIN on US03836N1037.

Aptinyx WKN on A2JPB1.

Aptinyx tähis on APTX.

Viimase 12 kuu jooksul maksis Aptinyx dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Aptinyx tõenäoliselt dividendi summas 0 USD.

Aptinyx praegune dividenditootlus on .

Aptinyx maksab kvartaalset dividendi. See makstakse välja kuudel .

Aptinyx maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 USD. See vastab dividenditootlusele 0 %.

Aptinyx on liigitatud sektorisse 'Tervis'.

Viimase Aptinyx dividendide saamiseks 29.12.2023 suuruses 0,099 USD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 2.1.2024.

Viimane dividendimakse toimus 29.12.2023.

Aastal 2023 maksis Aptinyx 0 USD dividende.

Aptinyx dividendid makstakse välja USD.